Review article: hypertonic saline use in the emergency department

In vitro effects of lactated Ringer's solution, hypertonic saline, hydroxyethyl starch, hypertonic saline/hydroxyethyl starch, and mannitol on thromboelastographic variables of canine whole blood

OBJECTIVE

To assess the in vitro effects of crystalloid and colloid IV fluids on the thromboelastographic (TEG) variables of canine whole blood.

DESIGN

In vitro experimental study.

SETTING

Veterinary teaching hospital.

ANIMALS

Twenty-two healthy dogs.

INTERVENTION

Citrated whole blood samples collected from healthy dogs were diluted with 3.4% hypertonic saline (HTS 3.4), 7% hypertonic saline (HTS 7), and 20% mannitol at 8% and 16% dilutions; hydroxyethyl starch 130/0.4 (HES 130/0.4) at 16% dilution; lactated Ringer's solution (LRS) at 16%, 33%, and 66% dilutions; and HTS 7-HES 130/0.4 at 25% and 50% dilutions. Kaolin-activated TEG analysis was concurrently performed on diluted and control (undiluted) samples.

MEASUREMENTS AND MAIN RESULTS

Dilution of canine whole blood with LRS compared to control reduced α angle and MA at both 33% (P = 0.009 and P = 0.011, respectively) and 66% dilution (P < 0.001 and P < 0.001, respectively), and prolonged K time at 66% dilution (P = 0.003). At 16% dilution, HTS 3.4, prolonged R time (P = 0.007), while mannitol, a fluid iso osmolar to HTS 3.4, prolonged K time (P = 0.006), reduced α angle (P < 0.001), MA (P = 0.046), and LY60 (P = 0.015). At 8% dilution, HTS 7, a fluid of high osmolarity and tonicity, prolonged R time (P = 0.009) and reduced MA (P = 0.015), while all measured TEG variables were altered at the 16% dilution (P < 0.01 for all variables). HES 130/0.4 reduced α angle (P = 0.031) and MA (P = 0.001) and increased LY60 (P < 0.001) at 16% dilution. Comparing different fluid types, HES 130/0.4 and HTS 3.4 had no to minor, mannitol intermediate, and HTS 7 profound effects on TEG variables (P < 0.05) when compared to LRS at the same dilution.

CONCLUSIONS

In vitro dilution of canine whole blood with commonly used IV fluids leads to thromboelastographic changes consistent with hypocoagulability in a dose dependent manner for all fluid types tested. Viscoelastic changes are also influenced by fluid characteristics, specifically tonicity and osmolarity.

The currency, completeness and quality of systematic reviews of acute management of moderate to severe traumatic brain injury: A comprehensive evidence map

OBJECTIVE

To appraise the currency, completeness and quality of evidence from systematic reviews (SRs) of acute management of moderate to severe traumatic brain injury (TBI).

METHODS

We conducted comprehensive searches to March 2016 for published, English-language SRs and RCTs of acute management of moderate to severe TBI. Systematic reviews and RCTs were grouped under 12 broad intervention categories. For each review, we mapped the included and non-included RCTs, noting the reasons why RCTs were omitted. An SR was judged as 'current' when it included the most recently published RCT we found on their topic, and 'complete' when it included every RCT we found that met its inclusion criteria, taking account of when the review was conducted. Quality was assessed using the AMSTAR checklist (trichotomised into low, moderate and high quality).

FINDINGS

We included 85 SRs and 213 RCTs examining the effectiveness of treatments for acute management of moderate to severe TBI. The most frequently reviewed interventions were hypothermia (n = 17, 14.2%), hypertonic saline and/or mannitol (n = 9, 7.5%) and surgery (n = 8, 6.7%). Of the 80 single-intervention SRs, approximately half (n = 44, 55%) were judged as current and two-thirds (n = 52, 65.0%) as complete. When considering only the most recently published review on each intervention (n = 25), currency increased to 72.0% (n = 18). Less than half of the 85 SRs were judged as high quality (n = 38, 44.7%), and nearly 20% were low quality (n = 16, 18.8%). Only 16 (20.0%) of the single-intervention reviews (and none of the five multi-intervention reviews) were judged as current, complete and high-quality. These included reviews of red blood cell transfusion, hypothermia, management guided by intracranial pressure, pharmacological agents (various) and prehospital intubation. Over three-quarters (n = 167, 78.4%) of the 213 RCTs were included in one or more SR. Of the remainder, 17 (8.0%) RCTs post-dated or were out of scope of existing SRs, and 29 (13.6%) were on interventions that have not been assessed in SRs.

CONCLUSION

A substantial number of SRs in acute management of moderate to severe TBI lack currency, completeness and quality. We have identified both potential evidence gaps and also substantial research waste. Novel review methods, such as Living Systematic Reviews, may ameliorate these shortcomings and enhance utility and reliability of the evidence underpinning clinical care.

ROC trials update on prehospital hypertonic saline resuscitation in the aftermath of the US-Canadian trials

The objectives of this review are to assess the current state of hypertonic saline as a prehospital resuscitation fluid in hypotensive trauma patients, particularly after the 3 major Resuscitation Outcomes Consortium trauma trials in the US and Canada were halted due to futility. Hemorrhage and traumatic brain injury are the leading causes of death in both military and civilian populations. Prehospital fluid resuscitation remains controversial in civilian trauma, but small-volume resuscitation with hypertonic fluids is of utility in military scenarios with prolonged or delayed evacuation times. A large body of pre-clinical and clinical literature has accumulated over the past 30 years on the hemodynamic and, most recently, the anti-inflammatory properties of hypertonic saline, alone or with dextran-70. This review assesses the current state of hypertonic fluid resuscitation in the aftermath of the failed Resuscitation Outcomes Consortium trials.

Intravenous hypertonic saline use in the pediatric emergency department

OBJECTIVES

The objective of this study was to describe the use, dosing, and administration of intravenous hypertonic saline (IHS) use in a pediatric emergency department.

METHODS

This was a retrospective chart review of patients 0 to 18 years receiving IHS as part of their management in a pediatric ED with an annual volume of more than 50,000 visits.

RESULTS

Over 4 years, 56 patients received IHS as part of their management in the emergency department. Clinical scenarios for IHS administration included traumatic brain injury with concern for increased intracranial pressure in 19 patients (34%), diabetic ketoacidosis with altered mental status in 18 (32%), hyponatremia without seizure activity in 6 (10.7%), hyponatremic seizure in 3 (5.4%), and altered mental status secondary to a nontraumatic, non-diabetic ketoacidosis cause in 10 (17.9%). The median age of the patients was 11.3 years (interquartile range, 6-13.9 years) receiving a median dose of 4.1 mL/kg (interquartile range, 3.08-5 mL/kg) of IHS. The median time for administration of the IHS was 17 minutes, with 87% of doses given via peripheral intravenous catheters. Approximately one fourth (26.8%) of patients received their dose in 10 minutes or less, with 7.2% of patients receiving a bolus of IHS in 3 minutes or less. We found no evidence of adverse effects.

CONCLUSIONS

Intravenous hypertonic saline use is increasing within the pediatric emergency department. Within this institution, it is most frequently used at a dosing range of 3 to 5 mL/kg and does not require central venous access for rapid infusion.

New and future resuscitation fluids for trauma patients using hemoglobin and hypertonic saline

Hemoglobin-based oxygen carriers (HBOC) and hypertonic saline solutions (HSS) are used for resuscitation of trauma patients with hemorrhagic shock. In this review, the clinical application, dosing, administration, and side effects of these solutions are discussed. Although HBOC and HSS are not ideal resuscitation fluids, until rapidly thawed universal donor frozen blood and blood component therapy becomes widely available in North America, these fluids should to be considered immediately after injury and throughout the spectrum of care for patients with hemorrhagic shock, until blood and blood components become available.

Hypertonic saline: a change of practice

BACKGROUND

This practice development review describes how the introduction of hypertonic saline in the treatment of raised intracranial pressure was brought about in one critical care unit. It considers the need for staff education and patient safety as an integral part of the change process.

AIM

The aim was to review making a practice change, using Lewin's three step change model and describes possible pitfalls in the process and ways of overcoming or avoiding them.

METHODS

The inclusion criterion for critiqued literature was: Worldwide, English language studies from the last 26 years. Exclusion was articles from non-academically recognized sources. The search was limited to primary and empirical sources.

DISCUSSION

This article uses Lewin's change model to describe driving and restraining forces, highlighting potential problems and suggesting ways in which they can be overcome when implementing a change in practice. Critical to the success of any change is the importance of evaluation, and suitable methods of evaluating the change are also suggested.

RELEVANCE TO CLINICAL PRACTICE

Critical care and neurosurgical nurses need to be aware of the potentially serious side effects, actions and correct methods of administration of hypertonic saline to ensure its safe use and ensure patient safety. Effects and side effects of hypertonic saline are described, highlighting the need for care in introducing such agents into a clinical area. The methodology used was an electronic search. The change in practice relates to the introduction of hypertonic saline, but could be adapted for any change in clinical nursing practice.

A comparison of hypertonic (7.2%) and isotonic (0.9%) saline for fluid resuscitation in horses: a randomized, double-blinded, clinical trial

BACKGROUND

Hypertonic saline solution (7.2%) (HSS) can quickly replace intravascular volume deficits. HSS more recently has been advocated in the treatment of traumatic brain injury, but its use in dehydrated patients remains controversial.

HYPOTHESIS

Hypertonic saline solution will show a significant improvement in both clinical and laboratory hydration parameters as compared to isotonic (0.9%) saline solution (ISS).

ANIMALS

Endurance horses eliminated from the 2009 Western States 100-mile (220-km) endurance ride and requiring IV fluid therapy were eligible for enrollment in the study.

METHODS

Twenty-two horses were randomly assigned to receive 4 mL/kg of either HSS or ISS along with 5 L lactated Ringer's solution (LRS). After this bolus, horses were treated with additional LRS in varying amounts. Blood and urine samples were collected before, during, and after treatment. Data were compared using 2-way ANOVA with repeated measures.

RESULTS

As compared to ISS, HSS horses showed greater decreases in PCV (P = .04), total protein (P = .01), albumin (P = .01), and globulin (P = .02) concentrations. HSS horses showed greater increases in sodium and chloride (P < .001) as compared to ISS horses. Horses receiving HSS had a shorter time to urination (P = .03) and lower specific gravity (P < .001) than those receiving ISS.

CONCLUSIONS

Results of this study indicate that HSS may provide faster restoration of intravascular volume deficits than ISS in endurance horses receiving emergency medical treatment. More marked electrolyte changes should be expected with HSS, however, and additional fluids after HSS administration likely are needed.

Resuscitation with hypertonic saline-dextran reduces serum biomarker levels and correlates with outcome in severe traumatic brain injury patients

In the treatment of severe traumatic brain injury (TBI), the choice of fluid and osmotherapy is important. There are practical and theoretical advantages to the use of hypertonic saline. S100B, neuron-specific enolase (NSE), and myelin-basic protein (MBP) are commonly assessed biomarkers of brain injury with potential utility as diagnostic and prognostic indicators of outcome after TBI, but they have not previously been studied in the context of fluid resuscitation. This randomized controlled trial compared serum concentrations of S100B, NSE, and MBP in adult severe TBI patients resuscitated with 250 mL of 7.5% hypertonic saline plus 6% dextran70 (HSD; n = 31) versus 0.9% normal saline (NS; n = 33), and examined their relationship with neurological outcome at discharge. Blood samples drawn on admission (<or=3 h post-injury), and at 12, 24, and 48 h post-resuscitation were assayed by ELISA for the selected biomarkers. Serial comparisons of biomarker concentrations were made by ANOVA, and relationships between biomarkers and outcome were assessed by multiple regression. On admission, mean (+/-SEM) S100B and NSE concentrations were increased 60-fold (0.73 +/- 0.08 microg/L) and sevenfold (37.0 +/- 4.8 microg/L), respectively, in patients resuscitated with NS, compared to controls (0.01 +/- 0.01 and 6.2 +/- 0.6, respectively). Compared with NS resuscitation, S100B and NSE were twofold and threefold lower in HSD-treated patients and normalized within 12 h. MBP levels were not significantly different from controls in either treatment arm until 48 h post-resuscitation, when a delayed increase (0.58 +/- 0.29 microg/L) was observed in NS-treated patients. Biomarkers were elevated in the patient group showing an unfavorable outcome. HSD-resuscitated patients with favorable outcomes exhibited the lowest serum S100B and NSE concentrations, while maximal levels were found in NS-treated patients with unfavorable outcomes. The lowest biomarker levels were seen in survivors resuscitated with HSD, while maximal levels were in NS-resuscitated patients with fatal outcome. Pre-hospital resuscitation with HSD is associated with a reduction in serum S100B, NSE, and MBP concentrations, which are correlated with better outcome after severe TBI.

Management of bleeding following major trauma: an updated European guideline

INTRODUCTION

Evidence-based recommendations are needed to guide the acute management of the bleeding trauma patient, which when implemented may improve patient outcomes.

METHODS

The multidisciplinary Task Force for Advanced Bleeding Care in Trauma was formed in 2005 with the aim of developing a guideline for the management of bleeding following severe injury. This document presents an updated version of the guideline published by the group in 2007. Recommendations were formulated using a nominal group process, the Grading of Recommendations Assessment, Development and Evaluation (GRADE) hierarchy of evidence and based on a systematic review of published literature.

RESULTS

Key changes encompassed in this version of the guideline include new recommendations on coagulation support and monitoring and the appropriate use of local haemostatic measures, tourniquets, calcium and desmopressin in the bleeding trauma patient. The remaining recommendations have been reevaluated and graded based on literature published since the last edition of the guideline. Consideration was also given to changes in clinical practice that have taken place during this time period as a result of both new evidence and changes in the general availability of relevant agents and technologies.

CONCLUSIONS

This guideline provides an evidence-based multidisciplinary approach to the management of critically injured bleeding trauma patients.